Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells

Molecular and Cellular Endocrinology

Volumn 196, Issue 1-2, 2002, Pages 11-20

  Hodges, Leslie C ^a   Houston, Kevin D ^a   Hunter, Deborah S ^a   Fuchs Young, Robin ^a   Zhang, Zhiming ^b   Wineker, Richard C ^b   Walker, Cheryl L ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Women's Health Research Institute   (United States)

Author keywords

Antiprogestins; PR A, PR B; Progesterone receptor; Progestins; Uterine leiomyoma; Uterine myometrium

Indexed keywords

ANTIGESTAGEN; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; PROGESTERONE RECEPTOR; PROMEGESTONE; RECEPTOR SUBTYPE; ESTRADIOL; LIGAND; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; ESTRUS CYCLE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MYOMETRIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; REPORTER GENE; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR CELL LINE; UTERUS MYOMA; ANIMAL; CELL CULTURE; CELL DIVISION; CYTOLOGY; DRUG EFFECT; GENETIC TRANSCRIPTION; LEIOMYOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; UTERUS CANCER;

ANIMALS; CELL DIVISION; ESTRADIOL; ESTROUS CYCLE; FEMALE; LEIOMYOMA; LIGANDS; MYOMETRIUM; PROGESTINS; RATS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS;

EID: 0037206412     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(02)00230-7     Document Type: Article

References (61)

1. Andersen J. Growth factors and cytokines in uterine leiomyomas. Semin. Reprod. Endocrinol. 14:1996;269-282.
2. Andersen J., Barbieri R.L. Abnormal gene expression in uterine leiomyomas. J. Soc. Gynecol. Investig. 2:1995;663-672.
3. Andersen J., DyReyes V.M., Barbieri R.L., Coachman D.M., Miksicek R.J. Leiomyoma primary cultures have elevated transcriptional response to estrogen compared with autologous myometrial cultures. J. Soc. Gynecol. Invest. 2:1995;542-551.
4. Andreyko J.L., Marshall L.A., Dumesic D.A., Jaffe R.B. Therapeutic uses of gonadotropin-releasing hormone analogs. Obstet. Gynecol. Surv. 42:1987;1-21.
5. Bowden R.T., Hissom J.R., Moore M.R. Growth stimulation of T47D human breast cancer cells by the anti-progestin RU486. Endocrinology. 124:1989;2642-2644.
6. Boyd P.A., Spelsberg T.C. Seasonal changes in the molecular species and nuclear binding of the chick oviduct progesterone receptor. Biochemistry. 18:1979;3685-3690.
7. Brandon D.D., Bethea C.L., Strawn E.Y., Novy M.J., Burry K.A., Harrington M.S., Erickson T.E., Warner C., Keenan E.J., Clinton G.M. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am. J. Obstet. Gynecol. 169:1993;78-85.
8. Brandon D.D., Erickson T.E., Keenan E.J., Strawn E.Y., Novy M.J., Burry K.A., Warner C., Clinton G.M. Estrogen receptor gene expression in human uterine leiomyomata. J. Clin. Endocrinol. Metab. 80:1995;1876-1881.
9. Burroughs K.D., Fuchs-Young R., Davis B., Walker C.L. Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat. Biol. Reprod. 63:2000;1322-1330.
10. Burroughs K.D., Kiguchi K., Howe S.R., Fuchs-Young R., Trono D., Barrett J.C., Walker C. Regulation of apoptosis in uterine leiomyomata. Endocrinology. 138:1997;3056-3064.
11. Burroughs K.D., Howe S.R., Okubo Y., Fuchs-Young R., LeRoith D., Walker C.L. Dysregulation of IGF-I signaling in uterine leiomyoma. J. Endocrinol. 172:2002;83-93.
12. Chalbos D., Galtier F. Differential effect of forms A and B of human progesterone receptor on estradiol-dependent transcription. J. Biol. Chem. 269:1994;23007-23012.
13. Cohen D., Mazur M.T., Jozefczyk M.A., Badawy S.Z. Hyalinization and cellular changes in uterine leiomyomata after gonadotropin releasing hormone agonist therapy. J. Reprod. Med. 39:1994;377-380.
14. Cramer S.F., Patel A. The frequency of uterine leiomyomas. Am. J. Clin. Pathol. 94:1990;435-438.
15. Easterday C.L., Grimes D.A., Riggs J.A. Hysterectomy in the United States. Obstet. Gynecol. 62:1983;203-212.
16. Edwards D.P., Leonhardt S.A., Gass-Handel E. Novel mechanisms of progesterone antagonists and progesterone receptor. J. Soc. Gynecol. Invest. 7:2000;S22-S24.
17. Englund K., Blanck A., Gustavsson I., Lundkvist U., Sjoblom P., Norgren A., Lindblom B. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J. Clin. Endocrinol. Metab. 83:1998;4092-4096.
18. Feil P.D., Clarke C.L., Satyaswaroop P.G. Progestin-mediated changes in progesterone receptor forms in the normal human endometrium. Endocrinology. 123:1988;2506-2513.
19. Freeman E. The neuroendocrine control of the ovarian cycle of the rat. Knobil E., The Physiology of Reproduction. 2nd ed. 1994;613-658 Raven Press, New York.
20. Fuchs-Young R., Howe S., Hale L., Miles R., Walker C. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol. Carcinog. 17:1996;151-159.
21. Fujimoto J., Hirose R., Ichigo S., Sakaguchi H., Li Y.L., Tamaya T. Expression of progesterone receptor form A and B mrnas in uterine leiomyoma. Tumor Biol. 19:1998;126-131.
22. Giangrande P.H., McDonnell D.P. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog. Horm. Res. 54:1999;291-313.
23. Hodges L.C., Bergerson J.S., Hunter D.S., Walker C.L. Estrogenic effects of organochlorine pesticides on uterine leiomyoma cells in vitro. Toxicol. Sci. 54:2000;355-364.
24. Horwitz K.B. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr. Rev. 13:1992;146-163.
25. Howe S.R., Everitt J.I., Gottardis M.M., Walker C. Estrogen/antiestrogen responsiveness in an in vivo/in vitro model for myometrial tumorigenesis. Ann. N. Y. Acad. Sci. 761:1995;373-375.
26. Howe S.R., Gottardis M.M., Everitt J.I., Goldsworthy T.L., Wolf D.C., Walker C. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am. J. Pathol. 146:1995;1568-1579.
27. Howe S.R., Gottardis M.M., Everitt J.I., Walker C. Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. Endocrinology. 136:1995;4996-5003.
28. Hunter D.S., Hodges L.C., Vonier P.M., Fuchs-Young R., Gottardis M.M., Walker C.L. Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium. Cancer Res. 59:1999;3090-3099.
29. Katzenellenbogen B.S. Mechanisms of action and cross-talk between estrogen receptor and progesterone receptor pathways. J. Soc. Gynecol. Invest. 7:2000;S33-S37.
30. Kawaguchi K., Fujii S., Konishi I., Nanbu Y., Nonogaki H., Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am. J. Obstet. Gynecol. 160:1989;637-641.
31. Kettel L.M., Murphy A.A., Morales A.J., Yen S.S. Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Hum. Reprod. 9:(Suppl. 1):1994;116-120.
32. Kirkland J.L., Murthy L., Stancel G.M. Progesterone inhibits the estrogen-induced expression of c-fos messenger ribonucleic acid in the uterus. Endocrinology. 130:1992;3223-3230.
33. Kraus W.L., Katzenellenbogen B.S. Regulation of progesterone receptor gene expression and growth in the rat uterus: modulation of estrogen actions by progesterone and sex steroid hormone antagonists. Endocrinology. 132:1993;2371-2379.
34. Kraus W.L., Montano M.M., Katzenellenbogen B.S. Identification of multiple, widely spaced estrogen-responsive regions in the rat progesterone receptor gene. Mol. Endocrinol. 8:1994;952-969.
35. Kraus W.L., Weis K.E., Katzenellenbogen B.S. Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol. Cell. Biol. 15:1995;1847-1857.
36. Krishnan V., Wang X., Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J. Biol. Chem. 269:1994;15912-15917.
37. L'Horset F., Blin C., Colnot S., Lambert M., Thomasset M., Perret C. Calbindin-D9k gene expression in the uterus: study of the two messenger ribonucleic acid species and analysis of an imperfect estrogen-responsive element. Endocrinology. 134:1994;11-18.
38. Lessey B.A., Killam A.P., Metzger D.A., Haney A.F., Greene G.L., McCarty K.S. Jr. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J. Clin. Endocrinol. Metab. 67:1988;334-340.
39. Lu K.H., Hopper B.R., Vargo T.M., Yen S.S. Chronological changes in sex steroid, gonadotropin and prolactin secretions in aging female rats displaying different reproductive states. Biol. Reprod. 21:1979;193-203.
40. Mangal R.K., Wiehle R.D., Poindexter A.N. III, Weigel N.L. Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J. Steroid Biochem. Mol. Biol. 63:1997;195-202.
41. Matsuo H., Maruo T., Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J. Clin. Endocrinol. Metab. 82:1997;293-299.
42. McDonnell D.P., Goldman M.E. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J. Biol. Chem. 269:1994;11945-11949.
43. Murphy A.A., Kettel L.M., Morales A.J., Roberts V.J., Yen S.S. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J. Clin. Endocrinol. Metab. 76:1993;513-517.
44. Nisolle M., Gillerot S., Casanas-Roux F., Squifflet J., Berliere M., Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum. Reprod. 14:1999;2844-2850.
45. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites [see comments]. Science. 277:1997;1508-1510.
46. Porter W., Saville B., Hoivik D., Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 11:1997;1569-1580.
47. Rein M.S., Nowak R.A. Biology of uterine myomas and myometrium in vitro. Semin. Reprod. Endocrinol. 10:1992;310-319.
48. Rein M.S., Friedman A.J., Stuart J.M., MacLaughlin D.T. Fibroid and myometrial steroid receptors in women treated with gonadotropin-releasing hormone agonist leuprolide acetate. Fertil. Steril. 53:1990;1018-1023.
49. Rein M.S., Barbieri R.L., Friedman A.J. Progesterone: a critical role in the pathogenesis of uterine myomas. Am. J. Obstet. Gynecol. 172:1995;14-18.
50. Romagnolo B., Molina T., Leroy G., Blin C., Porteux A., Thomasset M., Vandewalle A., Kahn A., Perret C. Estradiol-dependent uterine leiomyomas in transgenic mice. J. Clin. Invest. 98:1996;777-784.
51. Schneider W., Ramachandran C., Satyaswaroop P.G., Shyamala G. Murine progesterone receptor exists predominantly as the 83-kilodalton 'A' form. J. Steroid Biochem. Mol. Biol. 38:1991;285-291.
52. Shimomura Y., Matsuo H., Samoto T., Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J. Clin. Endocrinol. Metab. 83:1998;2192-2198.
53. Stewart E.A., Austin D.J., Jain P., Penglase M.D., Nowak R.A. RU486 suppresses prolactin production in explant cultures of leiomyoma and myometrium. Fertil. Steril. 65:1996;1119-1124.
54. Tung L., Mohamed M.K., Hoeffler J.P., Takimoto G.S., Horwitz K.B. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors [see comments] [published erratum appears in Mol. Endocrinol. 1993;7(11):1378]. Mol. Endocrinol. 7:1993;1256-1265.
55. Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B., Pike J.W., McDonnell D.P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8:1994;21-30.
56. Vegeto E., Shahbaz M.M., Wen D.X., Goldman M.E., O'Malley B.W., McDonnell D.P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function [see comments]. Mol. Endocrinol. 7:1993;1244-1255.
57. Viville B., Charnock-Jones D.S., Sharkey A.M., Wetzka B., Smith S.K. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Hum. Reprod. 12:1997;815-822.
58. Webb P., Lopez G.N., Uht R.M., Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9:1995;443-456.
59. Wen D.X., Xu Y.F., Mais D.E., Goldman M.E., McDonnell D.P. The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol. Cell. Biol. 14:1994;8356-8364.
60. Wu X., Blanck A., Olovsson M., Moller B., Favini R., Lindblom B. Apoptosis, cellular proliferation and expression of p53 in human uterine leiomyoms and myometrium during the menstrual cycle and after menopause. Acta Obstet. Gynecol. Scand. 79:2000;397-404.
61. Yuan Y.-D. Female reproductive system. Haschek W.M., Rousseaux C.G., Handbook of Toxicologic Pathology. 1987;891-935 Academic Press, New York.